Literature DB >> 12196308

Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years.

Baroukh M Assael1, Carlo Castellani, Marisol Barao Ocampo, Patrizia Iansa, Andrea Callegaro, Maria Grazia Valsecchi.   

Abstract

This population-based study was conducted in Veneto and Trentino (northwestern Italy, population 5 million). In this area, neonatal screening for cystic fibrosis started in 1973 and has been virtually universal since the early 1980s. During this study, the estimated incidence of cystic fibrosis in this region was 1/2,650 livebirths per year. The authors analyzed data on 593 patients born in 1938-2000 and living in the region who were followed by a single referral center. Median time from birth to confirmation of diagnosis after screening was 32 days (range, 0-1,531). For patients whose disease was recognized after symptoms occurred, median age at diagnosis was always less than 1 year. Median survival age was 37.7 years. Long-term survival (to age 20-30 years) was not significantly influenced by mode of diagnosis (screened or unscreened), sex, or age at diagnosis for unscreened patients (<1, 1-5, >5 years). Current survival analysis of three consecutive decades showed that improving survival tended to vanish in the last years of the study. The authors concluded that a regional neonatal screening program allows very early recognition of cystic fibrosis. They could not conclude that neonatal screening improves long-term survival if compared with diagnosis by symptoms in early infancy.

Entities:  

Mesh:

Year:  2002        PMID: 12196308     DOI: 10.1093/aje/kwf064

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  13 in total

Review 1.  Computed tomography dose optimisation in cystic fibrosis: A review.

Authors:  Helena Ferris; Maria Twomey; Fiachra Moloney; Siobhan B O'Neill; Kevin Murphy; Owen J O'Connor; Michael Maher
Journal:  World J Radiol       Date:  2016-04-28

2.  Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.

Authors:  Mareike Heimeshoff; Helge Hollmeyer; Jonas Schreyögg; Oliver Tiemann; Doris Staab
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.981

3.  Gender differences in outcomes of patients with cystic fibrosis.

Authors:  Cayce L Harness-Brumley; Alan C Elliott; Daniel B Rosenbluth; Deepa Raghavan; Raksha Jain
Journal:  J Womens Health (Larchmt)       Date:  2014-12       Impact factor: 2.681

4.  Cystic fibrosis: benefits and clinical outcome.

Authors:  K O McKay
Journal:  J Inherit Metab Dis       Date:  2007-07-06       Impact factor: 4.982

5.  Risk factors for the progression of cystic fibrosis lung disease throughout childhood.

Authors:  Don B Sanders; Zhanhai Li; Anita Laxova; Michael J Rock; Hara Levy; Jannette Collins; Claude Ferec; Philip M Farrell
Journal:  Ann Am Thorac Soc       Date:  2014-01

6.  Uncovering symptom progression history from disease registry data with application to young cystic fibrosis patients.

Authors:  Jun Yan; Yu Cheng; Jason P Fine; Huichuan J Lai
Journal:  Biometrics       Date:  2009-06-12       Impact factor: 2.571

7.  Validation and use of a parametric model for projecting cystic fibrosis survivorship beyond observed data: a birth cohort analysis.

Authors:  Abaigeal D Jackson; Leslie Daly; Andrew L Jackson; Cecily Kelleher; Bruce C Marshall; Hebe B Quinton; Godfrey Fletcher; Mary Harrington; Shijun Zhou; Edward F McKone; Charles Gallagher; Linda Foley; Patricia Fitzpatrick
Journal:  Thorax       Date:  2011-06-08       Impact factor: 9.139

8.  The cost-effectiveness of neonatal screening for cystic fibrosis: an analysis of alternative scenarios using a decision model.

Authors:  Neil Simpson; Rob Anderson; Franco Sassi; Alexandra Pitman; Peter Lewis; Karen Tu; Heather Lannin
Journal:  Cost Eff Resour Alloc       Date:  2005-08-09

9.  Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis.

Authors:  Richard Kraemer; David N Baldwin; Roland A Ammann; Urs Frey; Sabina Gallati
Journal:  Respir Res       Date:  2006-11-30

10.  S737F is a new CFTR mutation typical of patients originally from the Tuscany region in Italy.

Authors:  Vito Terlizzi; Antonella Miriam Di Lullo; Marika Comegna; Claudia Centrone; Elisabetta Pelo; Giuseppe Castaldo; Valeria Raia; Cesare Braggion
Journal:  Ital J Pediatr       Date:  2018-01-03       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.